Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis

Recruiting now · Not applicable

Conditions studied: Sepsis

In brief

The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of patients with critical infection, in the hope that the therapy will provide alternatives to the treatment of patients with critical infection.

Key facts

Study ID

NCT05634057

Run by

Chen Ying

People needed

782

Starts

2024-01-25

Expected to finish

2025-12-01

Last updated by the study team

2025-05-21

Who can join

Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than 18 years;
• Meets the diagnostic criteria for sepsis according to the "Sepsis-3" ;
• Patient or their legal representative consents to treatment and signs an informed consent form.

You may not qualify if…

• Patients expected to die within 24 hours after enrollment;
• Contraindications to low molecular weight heparin and scopolamine butylbromide drugs;
• Patients with thrombotic diseases requiring treatment with low molecular weight heparin;
• Patients with terminal-stage malignancies, severe immunodeficiency, immunosuppression, severe liver or kidney dysfunction (defined as liver or kidney SOFA score ≥ 3 points), etc.;
• Pregnant and lactating women;
• Patients participating in other clinical trials.

Where it is running

• Beijing Chaoyang Hospital, Capital Medical University — Beijing, China, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.